Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Purinergic P2 receptors are a family of cell surface receptors activated by extracellular nucleotides, primarily ATP. They are divided into two main subtypes: P2X receptors (ligand-gated ion channels) and P2Y receptors (G protein-coupled receptors). Expressed on various cell types, they regulate immune responses, neuronal signaling, vascular function, and mechanotransduction. Dysregulation is implicated in chronic inflammation, neurodegenerative disorders, and thrombosis, making them therapeutic targets.
Various, including receptor antagonism and ion channel blockade. Examples include clopidogrel inhibiting ADP-induced platelet aggregation via P2Y12 blockade, and specific inhibitors targeting neuroimmune functions mediated by ionotropic or metabotropic forms.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Purinergic P2 Receptor (P2 receptor).